ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Update

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) was the recipient of a large decrease in short interest in the month of February. As of February 15th, there was short interest totalling 7,100 shares, a decrease of 17.4% from the January 31st total of 8,600 shares. Based on an average daily volume of 11,700 shares, the short-interest ratio is currently 0.6 days.

Institutional Trading of ProShares UltraShort Nasdaq Biotechnology

An institutional investor recently raised its position in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC lifted its holdings in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) by 267.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 38,696 shares of the company’s stock after acquiring an additional 28,176 shares during the period. Jane Street Group LLC owned approximately 19.35% of ProShares UltraShort Nasdaq Biotechnology worth $704,000 as of its most recent filing with the SEC.

ProShares UltraShort Nasdaq Biotechnology Price Performance

Shares of ProShares UltraShort Nasdaq Biotechnology stock opened at $16.78 on Friday. ProShares UltraShort Nasdaq Biotechnology has a fifty-two week low of $14.05 and a fifty-two week high of $21.10. The firm has a fifty day moving average price of $17.13 and a two-hundred day moving average price of $16.15.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The business also recently declared a dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 23rd were issued a $0.2064 dividend. The ex-dividend date was Monday, December 23rd. This is an increase from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15.

ProShares UltraShort Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.